Buloxibutid
Idiopathic Pulmonary Fibrosis (Ipf)
Phase II
Recruiting
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
Sep 06, 2024
―
Drug Drug Interaction
Drug Interaction
Phase I
Completed
A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers
Mar 24, 2023
―
C21
Type2diabetes, Endothelial Dysfunction
Phase I
Completed
A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes
Mar 13, 2023
―
C106 Solution
Safety Issues, Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension, Tolerance
Phase I
Completed
First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects
Jun 07, 2022
―
C21, Sodium Nitroprusside
Study Vasodilatory Effects Of C21
Phase I
Completed
Effect of C21 on Forearm Blood Flow
Mar 03, 2022
―
C21
Idiopathic Pulmonary Fibrosis
Phase II
Completed
Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF
Aug 26, 2020
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Vicore Pharma Holding AB (6Y4) have in its pipeline
6Y4 is currently developing the following drugs: Buloxibutid, Drug Drug Interaction, C21. These drug candidates are in various stages of clinical development as the company works toward FDA approval.